Skip to main content

Table 1 Patient characteristics (N = 10) and responses

From: Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)

Patient
ID No.
Sex/
Age (years)
ECOG PS IELSG score* Disease state Previous therapy Tumor location R-B(O)AD cycles completed Final
response
PFS/OS (months)
1 F/68 2 5 Ref HDMTX+ AraC D; periventricular, basal ganglia 3 PD 1.8/7.3
2 F/55 2 4 Ref HDMTX+ AraC D; periventricular, corpus callosum 2 PD 2.5/6.8
3 M/75 1 4 Rel HDMTX + WBRT;
MPV-A
ND; L optic nerve 4 CR 21.7/> 21.7
4 M/42 2 3 Ref HDMTX D; basal ganglia 2 PD 1.6/9.1
5 M/78 2 3 Rel HDMTX+ AraC ND; L parietal 4 PR 6.9/> 6.9
6 F/55 2 4 Ref HDMTX+ AraC ND; L frontal, R temporal 3 PD 2.8/3.3
7 F/47 1 2 Ref HDMTX+ AraC Dt; L frontal, periventricular 1 PR 2.8/2.8
8 F/73 2 5 Rel HDMTX+ AraC ND; L frontal 4 PR 4.4/4.4
9 M/75 2 4 Ref HDMTX+ AraC NDt; L frontal 2 SD 4.2/> 4.2
10 M/65 2 5 Ref HDMTX Dt; L frontal, basal ganglia 2 PR 3.9/3.9
  1. Abbreviations: M, male; F, female; PS, performance status; Rel, relapsed; Ref, refractory; HDMTX, high dose methotrexate; AraC, cytarabine; WBRT, whole brain radiotherapy; MPV-A, methotrexate, vincristine, procarbazine, cytarabine; D, deep; ND, non-deep; L, left; R, right; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; OS, overall survival
  2. *IELSG risk = intermediate (IELSG score 2–3), high (IELSG score 4–5)
  3. tPatients with leptomeningeal involvement in recurrent disease